Elliot Antman, MD
|Hot Line I: Late Breaking Trials on Thrombosis|
Edoxaban for the Long-term Treatment of Venous Thromboembolism
Related StatisticsHeart Disease and Stroke Statistics: 2013 Update
Circulation. 2013;127:21-23, published online before print December 13 2012, doi:10.1161/CIRCULATIONAHA.112.155911
- Modeling suggests that >900 000 incident or recurrent VTE events occur annually in the United States, of which approximately one third are fatal. VTE incidence has not changed significantly over the past 25 years.
- PAD affects ≈8.5 million Americans aged ≥40 years and is associated with significant morbidity and mortality.42 PAD prevalence is higher in older individuals and appears to disproportionately affect African Americans.
- In the general population, only ≈10% of people with PAD have the classic symptom of intermittent claudication.
Go to Hot Line II: Late Breaking Trials on Intervention and Devices >>
Go to ESC Congress 13 Science News Home Page